|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
|
 |
 |
Gentris
Corporation Gentris Corporation is a pharmacogenomics company engaged in the development and rapid commercialization of innovative proprietary clinical pharmacogenomics products. Gentris believes that the application of pharmacogenomics knowledge to drug development will improve trial design and predictability, shortening the drug development cycle, improving new drug approval rates and market positioning, and enabling companies to retest drug candidates that fail to meet clinical trial or FDA approval standards. The Company is applying and commercializing genetic targets associated with patient response to drug treatment and disease susceptibility through highly accurate genotyping testing and reporting products for clinical use. Gentris is using the knowledge and expertise gained through the laboratory testing component to develop and commercialize Clinical Pharmacogenomic Diagnostic Kits. This testing stream of revenue will allow the company to develop the specialized products created by the demand from rapid adoption of pharmacogenomic testing as a standard of medical treatment. Click here for the latest news from Gentris.
|
|